- Home
- VLGEA vs CBLL Comparison
VLGEA vs CBLL Comparison
Compare VLGEA & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLGEA
- CBLL
- Stock Information
- Founded
- VLGEA 1937
- CBLL 2014
- Country
- VLGEA United States
- CBLL United States
- Employees
- VLGEA N/A
- CBLL N/A
- Industry
- VLGEA Food Chains
- CBLL
- Sector
- VLGEA Consumer Staples
- CBLL
- Exchange
- VLGEA Nasdaq
- CBLL Nasdaq
- Market Cap
- VLGEA 480.8M
- CBLL 433.7M
- IPO Year
- VLGEA N/A
- CBLL 2024
- Fundamental
- Price
- VLGEA $33.07
- CBLL $11.78
- Analyst Decision
- VLGEA
- CBLL Strong Buy
- Analyst Count
- VLGEA 0
- CBLL 5
- Target Price
- VLGEA N/A
- CBLL $24.20
- AVG Volume (30 Days)
- VLGEA 53.1K
- CBLL 290.1K
- Earning Date
- VLGEA 12-02-2025
- CBLL 11-04-2025
- Dividend Yield
- VLGEA 3.10%
- CBLL N/A
- EPS Growth
- VLGEA 12.16
- CBLL N/A
- EPS
- VLGEA 3.81
- CBLL N/A
- Revenue
- VLGEA $2,320,690,000.00
- CBLL $82,813,000.00
- Revenue This Year
- VLGEA N/A
- CBLL $35.50
- Revenue Next Year
- VLGEA N/A
- CBLL $28.24
- P/E Ratio
- VLGEA $8.68
- CBLL N/A
- Revenue Growth
- VLGEA 3.76
- CBLL 37.93
- 52 Week Low
- VLGEA $28.79
- CBLL $10.01
- 52 Week High
- VLGEA $40.15
- CBLL $32.75
- Technical
- Relative Strength Index (RSI)
- VLGEA 49.28
- CBLL 45.97
- Support Level
- VLGEA $30.90
- CBLL $10.85
- Resistance Level
- VLGEA $33.43
- CBLL $13.09
- Average True Range (ATR)
- VLGEA 0.87
- CBLL 0.66
- MACD
- VLGEA 0.19
- CBLL -0.16
- Stochastic Oscillator
- VLGEA 85.80
- CBLL 30.90
About VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.